×
Boundless Bio Pre-Tax Profit Margin 2023-2024 | BOLD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Boundless Bio pre-tax profit margin from 2023 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
View More
Boundless Bio Pre-Tax Profit Margin 2023-2024 | BOLD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Boundless Bio pre-tax profit margin from 2023 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$127.1B
Gilead Sciences (GILD)
$114.2B
Bristol Myers Squibb (BMY)
$112.1B
CSL (CSLLY)
$91B
Regeneron Pharmaceuticals (REGN)
$89.7B
GSK (GSK)
$74.4B
Argenex SE (ARGX)
$35.2B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Biogen (BIIB)
$25.4B
BioNTech SE (BNTX)
$25.4B
Illumina (ILMN)
$24.2B
Moderna (MRNA)
$19.9B
BeiGene (BGNE)
$19.7B
Incyte (INCY)
$15.6B
Genmab (GMAB)
$14.8B
Insmed (INSM)
$13B
Vaxcyte (PCVX)
$13B
BioMarin Pharmaceutical (BMRN)
$12.6B
Sarepta Therapeutics (SRPT)
$12.2B
Bio-Techne Corp (TECH)
$12B
Exelixis (EXEL)
$10.1B
Exact Sciences (EXAS)
$10.1B
QIAGEN (QGEN)
$10B
Revolution Medicines (RVMD)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$8.2B
Ascendis Pharma (ASND)
$7.8B